Targeted oncology

01 20 October 2026

DOI 10.1007/s11523-026-01237-w

Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer

Open DOI

Jacob Sands, Shun Lu, Joachim G. Aerts et al.

02 18 October 2026

DOI 10.1007/s11523-026-01260-x

Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit–Risk Assessment

Open DOI

Shugo Yajima, Gaku Okumura, Soichiro Yoshida et al.

03 17 October 2026

DOI 10.1007/s11523-026-01263-8

Association of TP53 Truncating Mutations with Time to Treatment Failure after First-Line Chemoimmunotherapy in HER2-Mutant Non-Small Cell Lung Cancer

Open DOI

Akihiro Yoshimura, Juichiro Yoshida, Chieko Takumi et al.

04 13 October 2026

DOI 10.1007/s11523-026-01250-z

A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives

Open DOI

Thanyanan Reungwetwattana, Kristin A. Higgins, Ignacio Casarini et al.

05 7 October 2026

DOI 10.1007/s11523-026-01258-5

Comment on: “First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies”

Open DOI

Reza Izadpanah, Eckhard U. Alt

06 7 October 2026

DOI 10.1007/s11523-026-01256-7

Perspectives on 10 years of Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: A Podcast

Open DOI

Shailender Bhatia, Sandra D’ANgelo, Paul Nghiem

07 4 October 2026

DOI 10.1007/s11523-026-01259-4

Beyond Contraindication-Based Selection: The Unmet Need for Predictive Biomarkers in First-Line Immunotherapy for Advanced HCC

Open DOI

Alireza Tojjari, Anwaar Saeed

Three immunotherapy-based regimens are now approved for first-line treatment of advanced hepatocellular carcinoma: atezolizumab plus bevacizumab, durvalumab plus tremelimumab (STRIDE), and nivolumab plus ipilimumab. Although each has dem...

Read abstract

08 2 October 2026

DOI 10.1007/s11523-026-01257-6

Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort Study

Open DOI

Petros Grivas, Piyush K. Agarwal, Hikmat Al-Ahmadie et al.

09 2 October 2026

DOI 10.1007/s11523-026-01255-8

Correction: Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure

Open DOI

Kwon Yong Tak, Hee Sun Cho, Jaejun Lee et al.

10 19 September 2026

DOI 10.1007/s11523-026-01245-w

Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

Open DOI

Veronique Dieras, Giuseppe Curigliano, Miguel Martin et al.

This is a summary of a research article reporting the findings of the HER2CLIMB-05 trial (NCT05132582), a randomized, double-blind, placebo-controlled, international, phase III trial. The HER2CLIMB-05 trial was conducted to compare the e...

Read abstract